Iluvien: Long-Acting Option for Diabetic Macular Edema – Study Results
New Data Support Use of Low-Dose Dexamethasone for DME
Table of Contents
New data presented at the American Academy of ophthalmology 2023 annual meeting support the use of low-dose dexamethasone intravitreal implant (ozurdex, Allergan) for the treatment of diabetic macular edema (DME). The data suggest that the implant can provide sustained vision gains and reduce the need for frequent anti-VEGF injections.
key Findings from the DATA Study
The DATA (Dexamethasone vs.Anti-VEGF for Diabetic Macular Edema) study was a randomized, controlled trial involving 300 patients with DME. Participants were randomized to receive either a 0.1 mg dexamethasone implant or intravitreal aflibercept (Eylea, Regeneron).
Here’s a breakdown of the key findings:
Vision gains: Patients in the dexamethasone group experienced statistically notable vision gains at 6 months, with a mean change in visual acuity of +0.48 letters. The aflibercept group showed a mean change of +0.35 letters.
Reduced Anti-VEGF Injections: The dexamethasone group required substantially fewer anti-VEGF rescue injections compared to the aflibercept group (0.4 vs. 1.8 injections, respectively).
Safety Profile: The safety profile of dexamethasone was consistent with previous studies, with the most common adverse events being increased intraocular pressure (IOP) and cataract progression. These events were generally manageable with topical medications or surgical intervention.
Long-Term Outcomes: Extended follow-up data showed that the vision gains observed at 6 months were maintained through 12 months, and the reduced need for anti-VEGF injections persisted.
Implications for Clinical Practice
These findings have vital implications for the management of DME. For years, anti-VEGF agents have been the mainstay of treatment, but they often require frequent injections to maintain efficacy. The DATA study suggests that a dexamethasone implant can be a valuable option, particularly for patients who:
Have a poor response to anti-VEGF therapy.
Require frequent anti-VEGF injections.
Prefer a less frequent treatment schedule.
“The DATA study provides compelling evidence that low-dose dexamethasone can be an effective and convenient treatment option for DME,” said David S. Boyer, MD, principal investigator of the study. “The reduced need for frequent injections can significantly improve patients’ quality of life and reduce the burden on healthcare systems.”
Understanding the Mechanism of Action
Dexamethasone is a corticosteroid that works by reducing inflammation in the retina. In DME, inflammation plays a key role in the breakdown of the blood-retinal barrier, leading to fluid leakage and macular swelling. By suppressing inflammation, dexamethasone helps to restore the integrity of the blood-retinal barrier and improve visual function.
The Ozurdex implant is a biodegradable implant that slowly releases dexamethasone over a period of up to 6 months. This sustained release provides a prolonged anti-inflammatory effect, reducing the need for frequent injections.
Considerations for Patient Selection and Monitoring
While the DATA study demonstrates the efficacy and safety of dexamethasone for DME, it’s importent to carefully select patients and monitor them closely.
Here are some key considerations:
IOP Monitoring: Patients receiving dexamethasone implants should be monitored regularly for increases in IOP. Topical medications or surgical intervention might potentially be necessary to control IOP.
Cataract Evaluation: Dexamethasone can accelerate cataract progression. Patients should be evaluated for cataracts before and during treatment.
Patient Education: Patients should be informed about the potential risks and benefits of dexamethasone therapy, including the possibility of increased IOP and cataract progression.
* Comorbidities: Consider the patient’s overall health and any existing comorbidities, such as glaucoma or diabetes, before initiating treatment.
Disclosure
Singer reports being a consultant and